Literature DB >> 17022202

Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.

David J Carlson1, Robert D Stewart, Vladimir A Semenenko.   

Abstract

The poor treatment prognosis for tumors with high levels of hypoxia is usually attributed to the decreased sensitivity of hypoxic cells to ionizing radiation. Mechanistic considerations suggest that linear quadratic (LQ) survival model radiosensitivity parameters for hypoxic (H) and aerobic (A) cells are related by alphaH = alphaA/oxygen enhancement ratio (OER) and (alpha/beta)H=OER(alpha/beta)A. The OER parameter may be interpreted as the ratio of the dose to the hypoxic cells to the dose to the aerobic cells required to produce the same number of DSBs per cell. The validity of these expressions is tested against survival data for mammalian cells irradiated in vitro with low- and high-LET radiation. Estimates of hypoxic and aerobic radiosensitivity parameters are derived from independent and simultaneous least-squares fits to the survival data. An external bootstrap procedure is used to test whether independent fits to the survival data give significantly better predictions than simultaneous fits to the aerobic and hypoxic data. For low-LET radiation, estimates of the OER derived from the in vitro data are between 2.3 and 3.3 for extreme levels of hypoxia. The estimated range for the OER is similar to the oxygen enhancement ratios reported in the literature for the initial yield of DSBs. The half-time for sublethal damage repair was found to be independent of oxygen concentration. Analysis of patient survival data for cervix cancer suggests an average OER less than or equal to 1.5, which corresponds to a pO2 of 5 mm Hg (0.66%) in the in vitro experiments. Because the OER derived from the cervix cancer data is averaged over cells at all oxygen levels, cells irradiated in vivo under extreme levels of hypoxia (<0.5 mm Hg) may have an OER substantially higher than 1.5. The reported analyses of in vitro data, as well as mechanistic considerations, provide strong support for the expressions relating hypoxic and aerobic radiosensitivity parameters. The formulas are also useful for the analysis of clinical data because the number of radiosensitivity parameters that need to be determined is reduced from four to three without a substantial decrease in the ability of the LQ to accurately predict the surviving faction. The relationships among radiosensitivity parameters imply that the dose to the hypoxic subvolume of the tumor needs to be escalated by a factor of the OER to achieve the same level of tumor control as in well oxygenated tumor regions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022202     DOI: 10.1118/1.2229427

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  28 in total

1.  Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.

Authors:  David J Carlson; Paul J Keall; Billy W Loo; Zhe J Chen; J Martin Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-22       Impact factor: 7.038

2.  Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.

Authors:  Olivia J Kelada; Sara Rockwell; Ming-Qiang Zheng; Yiyun Huang; Yanfeng Liu; Carmen J Booth; Roy H Decker; Uwe Oelfke; Richard E Carson; David J Carlson
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 3.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

4.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Authors:  Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

5.  Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.

Authors:  Kristi Hendrickson; Mark Phillips; Wade Smith; Lanell Peterson; Kenneth Krohn; Joseph Rajendran
Journal:  Radiother Oncol       Date:  2011-08-27       Impact factor: 6.280

6.  Radiation Promptly Alters Cancer Live Cell Metabolic Fluxes: An In Vitro Demonstration.

Authors:  David Campos; Wenny Peeters; Kwangok Nickel; Brian Burkel; Johan Bussink; Randall J Kimple; Albert van der Kogel; Kevin W Eliceiri; Michael W Kissick
Journal:  Radiat Res       Date:  2016-04-29       Impact factor: 2.841

7.  On the importance of prompt oxygen changes for hypofractionated radiation treatments.

Authors:  Michael Kissick; David Campos; Albert van der Kogel; Randall Kimple
Journal:  Phys Med Biol       Date:  2013-09-24       Impact factor: 3.609

8.  Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.

Authors:  B Henriques de Figueiredo; C Zacharatou; S Galland-Girodet; J Benech; H De Clermont-Gallerande; F Lamare; M Hatt; L Digue; E De Mones del Pujol; P Fernandez
Journal:  Strahlenther Onkol       Date:  2014-09-23       Impact factor: 3.621

9.  High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors.

Authors:  Olivia J Kelada; Roy H Decker; Sameer K Nath; Kimberly L Johung; Ming-Qiang Zheng; Yiyun Huang; Jean-Dominique Gallezot; Chi Liu; Richard E Carson; Uwe Oelfke; David J Carlson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-01       Impact factor: 7.038

10.  Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response.

Authors:  J Jeong; K I Shoghi; J O Deasy
Journal:  Phys Med Biol       Date:  2013-06-21       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.